Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284804 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00284804 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 74 participants.
The verdict
NCT00284804, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study is designed to determine the objective response rate in patients with relapsed or refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or gemcitabine alone.
Interventions
- DRUG MDX-060
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00284804
The ClinicalTrials.gov registry entry for NCT00284804 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-060 is the first listed.
NCT00284804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00284804 about?
NCT00284804 is a clinical study titled "A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease". This study is designed to determine the objective response rate in patients with relapsed or refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or gemcitabine alone.
What is the current status of trial NCT00284804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2005-11. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00284804?
The interventions under investigation include: MDX-060 (DRUG).
Who is sponsoring clinical trial NCT00284804?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.